{
  "id": 20618175,
  "title": "Phathom at jefferies global healthcare conference: growth meets access hurdles",
  "url": "https://urgent.news/2026/11/18/phathom-at-jefferies-global-healthcare-conference-growth-meets-access",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-18T16:12:19.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/transcripts/phathom-at-jefferies-global-healthcare-conference-growth-meets-access-hurdles-93CH-5036634"
  },
  "original_language": "en",
  "account": null,
  "summary": "Phathom Pharmaceuticals (PHAT) recently discussed its growth story for VOQUEZNA, an acid-suppression drug for gastroesophageal reflux disease, at the Jefferies Global Healthcare Conference. The company highlighted strong commercial momentum and a potential second growth engine in new indications, even though its shares traded lower and remained near the bottom of their 52-week range. VOQUEZNA generated $55 million in 2024, $175 million in 2025, and is projected to reach $310 million to $325 million in 2026, with management aiming for 20% to 30% of a 20 million-script market, potentially reaching $1 billion in gastroenterology sales. However, prior authorization and physician workflow remain major hurdles for faster growth.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}